TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03970772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Injection
Description: Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Tablets
Description: Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
Study: NCT02395003

Intervention type: OTHER
Intervention: Palmitate Diet
Description: Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.

Intervention type: OTHER
Intervention: Palmitate Diet
Description: Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
Study: NCT04919421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental injection and topical gel application
Description: Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental injection and virtual reality device
Description: Dental injection will be made while the participants are wearing virtual reality device.
Study: NCT03494595

Intervention type: PROCEDURE
Intervention: Pediatric Liver transplantation
Description: Pediatric Liver transplantation

Intervention type: PROCEDURE
Intervention: Pediatric Liver transplantation
Description: Pediatric Liver transplantation
Study: NCT01667783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Banding
Description: Laparoscopic Adjustable Gastric Banding using the LapBand

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Weight Loss
Description: Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass
Study: NCT06317246

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Investigation of BRAF mosaicism
Description: The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
Study: NCT00066131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal scaling and root planing
Description: Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
Study: NCT03491449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Maintaining a systolic blood pressure \<185mm Hg for 72 hours.
Study: NCT02031848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessments and Diet Intake
Study: NCT04596956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate Ringer injection
Description: Used in surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Used in surgery
Study: NCT03501680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis
Description: Triglyceridemia should be less than 5.65 mmol/l.
Study: NCT02268669

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reperfusion strategies
Description: Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reperfusion strategies
Description: Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
Study: NCT02992171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care management by oncology nurses
Description: The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
Study: NCT02565095

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stimulation of the carotid baroreceptors with a pressure system
Description: In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
Study: NCT04291066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
Study: NCT01964664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: 6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio Group
Description: Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
Study: NCT00996671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: focal adhesion kinase inhibitor given as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: focal adhesion kinase inhibitor given as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be used as comparator for GSK2256098
Study: NCT03665909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote activity monitoring system
Description: The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
Study: NCT02687048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago Exercise program
Description: The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago Exercise program
Description: The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful meditation
Description: Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
Study: NCT00265733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Study: NCT02457429

Intervention type: DEVICE
Group type: OTHER
Intervention: Experiemental diagnostic procedure: Dx-pH measurement system
Description: The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Peptest assay
Description: A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.

Intervention type: OTHER
Group type: OTHER
Intervention: GORD symptom questionnaire
Description: A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
Study: NCT01868841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AdreView
Description: 10 millicurie of AdreView (123I-mIBG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AdreView
Description: 10 millicurie of AdreView (123I-mIBG)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Study: NCT04193566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forxiga
Description: Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Forxiga
Description: Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.
Study: NCT00414297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECP Therapy
Description: application of ECP Therapy to CAD Patients

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ECP Therapy
Description: application of ECP Therapy to CAD Patients
Study: NCT02983708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (mPBMC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02230397

Intervention type: OTHER
Group type: OTHER
Intervention: plantaricin a (active product)
Description: Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage

Intervention type: OTHER
Group type: OTHER
Intervention: placebo product
Description: Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
Study: NCT01624519

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Lactate Analysis
Description: When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
Study: NCT04165538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombelastograph and surgical timing
Description: Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of \> 50 mm, 30-50 mm and \< 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
Study: NCT01152203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle
Study: NCT05976399

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Massage
Description: In participants in the CTM group, the treatment was started with the sacral region called the basic region and the whole back was treated. Pulls in the interscapular region were more intense than in other regions. After the interscapular region, the cervical, clavicular, and facial regions were also included in the treatment. Both short and long pulls were used according to the region during CTM. The applications first started with the basic region and then progressed to the lower thoracic, scapular, and interscapular regions. Then, the cervical and clavicular regions were treated. In each region, the applications were performed three times on each of the right and left sides. While positioning the patients, we paid attention to their privacy and the temperature of the room where the treatment was carried out. A total of 12 sessions, which were conducted 2 days a week and took 6 weeks, were performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymph Drainage
Description: The patients, who had filled out their pain diary before and submitted a consent form, were first evaluated before the treatment and then they lay on their back with their neck area open, paying attention to the protection of their privacy. Hand strokes, one of the basic techniques applied for treatment, were planned in accordance with the anatomy and physiology of the lymphatic system. MLD was applied to the lateral neck and face region in 5-7 repetitions so that the lymph collectors could give an adequate reaction to the application. The treatment was performed 2 days a week for 6 weeks, with a total of 12 sessions. Each session lasted 45 minutes.
Study: NCT04276038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-Cure laser pro
Description: The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: B-Cure laser pro
Description: The B-Cure laser pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2. The device is used at home and is self-applied by the patient. The device is AMAR approved (approval # 14810408) for pain reduction and for ulcer treatment. The device is also approved for marketing in Canada and as a medical device in Europe (CE medical mark).
Study: NCT00717457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 5mg twice daily for 4 weeks followed by 10mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg once weekly for 4 weeks followed by 20mg once weekly
Study: NCT01836419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic LMA insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: classic LMA insertion
Study: NCT05123456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Comparative X-ray of the single knee at 30 ° flexion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiography
Description: Comparative X-ray of the single knee at 30 ° flexion.
Study: NCT02620345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone M ( case 1 )
Description: Dydrogesterone Multivitamin nature~* Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~* 1tablet/24 hours/day (to 4 weeks after postpartum)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone M ( case 2 )
Description: Dydrogesterone Multivitamin nature~* Fibroids/ Women of Reproductive age ( discovered fibroids )~* 1tablet/24 hours/day ( from discovered fibroids through 6 months)
Study: NCT01229020

Intervention type: OTHER
Intervention: Observational study - no intervention
Description: Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
Study: NCT00469586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 4 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, post-prandial, inhalation.
Study: NCT04659109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glenzocimab
Description: IV administration as a sterile product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV administration
Study: NCT01240005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCIK
Description: Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
Study: NCT04442906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group BD received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml dexmedetomidine (100 ug).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Group BF received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 fentanyl (50 ug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Group B received Intra-articular injection of 20 ml bupivacaine 0.25%+ 1 ml saline.
Study: NCT01616732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: TU im

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo im
Study: NCT01695551

Intervention type: OTHER
Intervention: Data Collection Forms
Description: Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.